INR 157.15
(2.23%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 884.58 Million INR | -16.43% |
2022 | 1.05 Billion INR | -38.5% |
2021 | 1.72 Billion INR | -19.98% |
2020 | 2.15 Billion INR | -0.08% |
2019 | 2.15 Billion INR | 26.54% |
2018 | 1.7 Billion INR | -3.53% |
2017 | 1.76 Billion INR | -14.82% |
2016 | 2.07 Billion INR | 7.57% |
2015 | 1.92 Billion INR | -17.11% |
2014 | 2.32 Billion INR | -15.03% |
2013 | 2.73 Billion INR | 24.69% |
2012 | 2.19 Billion INR | 5.89% |
2011 | 2.06 Billion INR | -2.98% |
2010 | 2.13 Billion INR | 19.17% |
2009 | 1.78 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -682.65 Million INR | -177.17% |
2023 Q3 | - INR | -100.0% |
2023 Q1 | - INR | -100.0% |
2023 Q4 | 884.58 Million INR | 0.0% |
2023 Q2 | 836.14 Million INR | 0.0% |
2023 FY | 884.58 Million INR | -16.43% |
2022 Q2 | 1.68 Billion INR | 0.0% |
2022 FY | 1.05 Billion INR | -38.5% |
2022 Q1 | - INR | -100.0% |
2022 Q4 | 1.05 Billion INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 Q4 | 1.72 Billion INR | 0.0% |
2021 FY | 1.72 Billion INR | -19.98% |
2021 Q2 | 1.75 Billion INR | 0.0% |
2020 Q4 | 2.15 Billion INR | 0.0% |
2020 FY | 2.15 Billion INR | -0.08% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 2.18 Billion INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2019 Q4 | 2.15 Billion INR | 0.0% |
2019 FY | 2.15 Billion INR | 26.54% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 1.76 Billion INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2018 Q4 | 1.7 Billion INR | 0.0% |
2018 FY | 1.7 Billion INR | -3.53% |
2018 Q1 | - INR | 0.0% |
2017 FY | 1.76 Billion INR | -14.82% |
2016 FY | 2.07 Billion INR | 7.57% |
2016 Q4 | 2.06 Billion INR | 0.0% |
2016 Q2 | 2.09 Billion INR | 0.0% |
2016 Q3 | - INR | -100.0% |
2016 Q1 | - INR | -100.0% |
2015 FY | 1.92 Billion INR | -17.11% |
2015 Q4 | 1.92 Billion INR | 2.4% |
2015 Q3 | 1.87 Billion INR | 0.0% |
2015 Q2 | 1.87 Billion INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2014 Q1 | 3.03 Billion INR | 0.0% |
2014 Q4 | 2.32 Billion INR | 0.0% |
2014 FY | 2.32 Billion INR | -15.03% |
2013 Q1 | - INR | -100.0% |
2013 Q3 | - INR | -100.0% |
2013 Q2 | 2.12 Billion INR | 0.0% |
2013 FY | 2.73 Billion INR | 24.69% |
2012 Q4 | 2.19 Billion INR | 0.0% |
2012 FY | 2.19 Billion INR | 5.89% |
2011 FY | 2.06 Billion INR | -2.98% |
2010 FY | 2.13 Billion INR | 19.17% |
2009 FY | 1.78 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alfavision Overseas (India) Limited | 1.36 Billion INR | 35.238% |
Biocon Limited | 307.95 Billion INR | 99.713% |
Blue Jet Healthcare Limited | 2.13 Billion INR | 58.591% |
Concord Biotech Limited | 1.74 Billion INR | 49.18% |
Dishman Carbogen Amcis Limited | 39.53 Billion INR | 97.763% |
FERMENTA BIOTECH LIMITED | 2.62 Billion INR | 66.323% |
GENOMIC VALLEY BIOTECH LIMITED | 7.91 Million INR | -11074.498% |
Panacea Biotec Limited | 4.02 Billion INR | 77.996% |
SAMSRITA LABS LIMITED | 32.93 Million INR | -2585.857% |
Servoteach Industries Limited | 5275.00 INR | -16769321.801% |
SMS Lifesciences India Limited | 1.96 Billion INR | 55.07% |
Supriya Lifescience Limited | 1.05 Billion INR | 16.446% |
Syngene International Limited | 18.93 Billion INR | 95.329% |
TAKE Solutions Limited | 969.78 Million INR | 8.785% |
Titan Biotech Limited | 231.28 Million INR | -282.463% |
Transgene Biotek Limited | 393.11 Million INR | -125.022% |
Vanta Bioscience Limited | 724.23 Million INR | -22.141% |